Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic Colorectal Cancer|Triple Negative Breast Cancer|Prostate Adenocarcinoma|Stomach Adenocarcinoma|Esophageal Adenocarcinoma
Interventions: DRUG: Tremelimumab|DRUG: Durvalumab
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris